Alex Cohen, MD
Ophthalmology · Phoenix, AZNPI 1497953673
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Alcon at 30.7% of the total.
Across 159 payments — averaging $63.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Sight Sciences, Inc.$2K
- Glaukos Corporation$2K
- Digital Diagnostics Inc.$800
- AbbVie$467
- Biotissue Holdings Inc.$331
- plus $2K from 24 others
Across 30 payments — averaging $562.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$8K
- Glaukos Corporation$7K
- Digital Diagnostics Inc.$2K
What the payments were for
- Consulting fees$4,10040%
- Travel & lodging$1,57916%
- Food & beverage$4,39143%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 57 | $3,120 |
| Sight Sciences, Inc. | 11 | $2,234 |
| Glaukos Corporation | 4 | $1,559 |
| Digital Diagnostics Inc. | 1 | $800 |
| AbbVie(2 entities) | 23 | $467 |
| Biotissue Holdings Inc. | 9 | $331 |
| Novartis | 9 | $213 |
| Dompe US, Inc. | 7 | $209 |
| Alimera Sciences, Inc. | 2 | $203 |
| Tarsus Pharmaceuticals, Inc. | 4 | $127 |
| Coopervision Inc. | 1 | $115 |
| The Cameron-ehlen Group, Inc. | 1 | $95 |
| Rayner Intraocular Lenses Limited | 3 | $87 |
| Bausch & Lomb Americas Inc. | 4 | $80 |
| Genentech USA, Inc. | 2 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Sun Pharmaceutical Industries Inc. | 2 | $55 |
| Biogen | 2 | $48 |
| Boston Scientific | 2 | $36 |
| Harrow Eye, LLC | 1 | $29 |
| Amgen | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Tearlab Corp | 1 | $13 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
| Rxsight Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$2,000
- Travoprost Intraocular Implant - iDose$1,300
- IDx-DR$800
- AIR OPTIX$610
- DAILIES$521
- iStent Infinite$222
- Iluvien$162
- DAILIES TOTAL1$120
- Precision7$120
- TOTAL30$120
- Precision 1$120
- MyDay Contact Lens$115
- Rocklatan$113
How this compares
$10,150 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 464 | $24,628 |
| RestasisCyclosporine | 22 | $19,594 |
| LumiganBimatoprost | 27 | $11,003 |
| Ketorolac Tromethamine | 194 | $6,360 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,052 |
| Latanoprost | 99 | $805 |
| Timolol Maleate | 55 | $328 |
| Dorzolamide Hcl | 15 | $283 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $281 |
| Ofloxacin | 21 | $242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $467 | $30,59749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.